Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
338 Leser
Artikel bewerten:
(1)

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

MOSCOW, July 12, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), investor in the Russian Sputnik V vaccine against coronavirus, today announced results of a study in Argentina on vaccine's IgG anti-spike titers and neutralizing capacity in non-infected and previously infected persons among healthcare workers.

Russian Direct Investment Fund

The study has been published in an international peer-reviewed, open access Cell Reports Medicine journal: https://www.sciencedirect.com/science/article/pii/S2666379121002081

The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.

There were 39 authors of the study including scientists Andres H. Rossi, Diego S. Ojeda, Augusto Varese, Lautaro Sanchez, Maria M. Gonzalez Lopez Ledesma, Ignacio Mazzitelli, and others. Among key findings in the article they note that the first dose of Sputnik V induced strong immune response in 94% of individuals previously not infected with COVID. It is also noted that there is no evident benefit of using a second dose in previously infected individuals. In authors' opinion, vaccination with only the first component of Sputnik V (Sputnik Light vaccine) is sufficient to protect previously infected individuals.

To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people. The real world data obtained during the vaccination of the population in a number of countries, including Mexico, Argentina, Serbia, Bahrain, San Marino, Hungary, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), commented:

"The piece published by experts from Argentina in Cell Reports Medicine journal is yet another example of a set of strong and positive data on real-world use of Sputnik V vaccine. It provides high-level protection for both previously non-infected individuals and those previously infected with COVID. Evidence is growing that Sputnik V is one of the safest and most effective vaccines against COVID in the world as confirmed by a set of data from regulators and scientific institutions in Latin America, Europe and the Middle East."

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 mn people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

Logo - https://mma.prnewswire.com/media/1140939/Russian_Direct_Investment_Fund_Logo.jpg

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.